Mayne Pharma Earnings Call Balances Growth And Risk

Mayne Pharma Group Ltd. ((AU:MYX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Mayne Pharma’s latest earnings call painted a cautiously optimistic picture, with management stressing stronger margins, solid cash generation and a profitable Dermatology turnaround alongside clear momentum in key Women’s Health brands. Yet investors were warned about an 8% drop in underlying EBITDA, heavy one‑off charges, rising legal and earn‑out outflows and pressure points around ANNOVERA and International investments.

Revenue Flat But Margins Move Higher

Group revenue held broadly steady at $212.1 million year‑on‑year, but the quality of those sales improved as gross margin rose to 65.3% from 61.4%. Management framed the near‑4 percentage‑point margin expansion as evidence of a better product mix and tighter margin control rather than volume growth.

Stronger Direct Contribution Signals Higher-Quality Earnings

Total direct segment contribution climbed to $68.1 million, up $3.1 million or roughly 5% compared with the prior period. That increase, delivered despite flat group revenue, underlined management’s argument that the business is shifting toward more profitable branded franchises.

Cash Generative Core And Solid Liquidity

Adjusted operating cash flow from continuing operations reached $16.9 million, confirming that the underlying business remained cash generative through the half. The company ended the period with $67.3 million in cash and marketable securities, providing a buffer to fund ongoing investment and manage legal and earn‑out obligations.

Dermatology Delivers Margin-Led Turnaround

Dermatology revenue slipped 3% to $78.6 million, but profitability improved sharply with gross margin jumping to 65% and direct contribution up 35% to $29.8 million. The reshaped portfolio now leans harder into branded products, which generated $51.2 million and rose to 65% of segment revenue versus 55% a year earlier.

Women’s Health Shows Broad-Based Product Momentum

Women’s Health revenue inched up 2% to $96.5 million, supported by volume and sales gains across NEXTSTELLIS, BIJUVA and IMVEXXY. NEXTSTELLIS demand cycles advanced 16% with net sales up 4%, while IMVEXXY and BIJUVA delivered modest to strong growth in prescriptions and net sales, reinforcing the menopause franchise as a core growth engine.

International: PBS Listing And Manufacturing Upgrade

International operations entered an investment-heavy phase as NEXTSTELLIS secured PBS approval in Australia and promotional efforts ramped. Mayne also completed an $18 million modernization of its Salisbury manufacturing facility, with early signs of traction including a reported 118% uplift in 3‑pack NEXTSTELLIS volumes in December 2025.

Strategic Repositioning And Leadership Continuity

Management declared the transformation from a generics and CDMO player into a U.S.-focused branded Women’s Health and Dermatology company effectively complete. A planned CEO succession has been executed, and the board emphasized that experienced leadership and a clearer strategic identity should support more predictable execution.

Capital Allocation Optionality Back On The Table

With the balance sheet strengthened and the core franchises maturing, Mayne is actively assessing how best to deploy capital. Options under review include potential share buybacks, targeted bolt‑on acquisitions and stepped‑up promotional spending to accelerate growth in high‑margin brands.

Underlying EBITDA Under Pressure

Underlying EBITDA fell 8% to $28.6 million, reflecting stepped‑up promotional spend in Women’s Health and other discrete costs tied to the strategic transition. Management argued that these investments are designed to protect and extend future growth, yet they temporarily dilute near‑term earnings.

Heavy One-Off And Noncash Charges Cloud Reported Results

Headline profitability was weighed down by a $54.5 million noncash earn‑out reassessment and $21.3 million of diligence, business development, litigation and restructuring expenses. These items introduced volatility into reported EBITDA, prompting the company to steer investors toward underlying performance metrics.

Legal And Transaction Costs Remain Elevated

Scheme‑related transaction and litigation expenses totaled $20.7 million during the half, adding to the drag on reported earnings. Additional outflows included $7.3 million in royalties and $10.3 million tied to the acquisition of TWYNEO and EPSOLAY intangibles, underscoring the cash cost of portfolio reshaping.

Women’s Health Profitability Squeezed By Investment

While top line trends in Women’s Health were positive, profitability softened as gross profit edged down 1% to $76.2 million and gross margin slipped three percentage points to 79%. Direct operating costs in the segment rose 6% to $40 million, pushing direct contribution down 8% to $36.2 million as Mayne invested behind future growth.

ANNOVERA Growth Masked By Returns Issue

ANNOVERA prescriptions increased 2%, but net sales fell 9% to $14.4 million after about $1.7 million of product returns in the half. Management highlighted higher‑than‑desired return and abandonment rates on ANNOVERA and is working on commercial adjustments to improve conversion of demand into revenue.

International Earnings Hit By Investment Phase

International revenue dipped 1% to $36.9 million, yet higher promotion costs drove a 32% jump in direct operating expenses to $9.2 million. As a result, direct contribution plunged 42% to $2.1 million, a decline management attributed to deliberate investment following PBS listing rather than structural weakness.

RHOFADE Faces Looming Generic Competition

RHOFADE, acquired out of bankruptcy and rapidly monetized, has so far delivered an attractive payback for Mayne. However, the company cautioned that generic competition is expected around the end of fiscal 2026, which could materially pressure this revenue stream and require offsetting growth elsewhere.

Persistent Litigation Overhang With Cosette

Mayne is pursuing proceedings in the Supreme Court of New South Wales against Cosette and related parties, seeking substantial damages. Ongoing legal action, potential appeals and associated costs may continue to generate uncertainty and weigh on earnings volatility over the medium term.

Guidance: Investing For Growth While Guarding Cash

Looking ahead, Mayne plans to invest selectively to capture market share and further expand margins in its core franchises while maintaining disciplined cash management. Management expects to grow Women’s Health, scale Dermatology’s disintermediation strategy from Q3 FY26 and unlock International value from NEXTSTELLIS’s PBS listing and the Salisbury upgrade, while litigation and FDA study costs are projected to ease and capital deployment options remain under review.

Mayne Pharma’s call ultimately balanced credible operational progress with clear risk disclosures, leaving investors weighing short‑term earnings pressure against a cleaner, higher‑margin business mix. With Women’s Health and Dermatology now firmly at the center of the strategy and International poised for a potential step‑up, the stock’s appeal will hinge on execution, legal outcomes and how management chooses to deploy its growing financial flexibility.